Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr Missing | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency KEL Cancer Info Ctr | Available |
Polices and Procedures for Infusion Therapy is a companion product to the Infusion Therapy Standards of Practice (the Standards), 8th edition. Evidence-based guidance for clinical practice has been derived directly from the Standards, including associated references, glossary of terms, abbreviation…
Table of Contents:; 1. Radiation Dermatitis -- 2. Hair Loss -- 3. Radiation Brain Injury -- 4. Radiation Orbital Toxicity -- 5. Ear Toxicity -- 6. Oral Mucositis -- 7. Xerostomia -- 8. Loss of Taste -- 9. Laryngeal Edema -- 10. Radiation Pneumonitis -- 11. Pericarditis -- 12. Esophagitis -- 13. Ra…
c.1 BC Cancer Agency KEL Library | Available |
Contents:; Overview of Cancer-Associated Thrombosis -- Pathophysiology and Risk Factors for Cancer-Associated Thrombosis -- Impact of Venous Thromboembolism on Cancer Survival -- Occult Cancer Workup in Idiopathic Venous Thromboembolism -- Chemotherapy Induced Thrombosis -- Catheter-Related Thrombo…
"Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia…
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.3 BC Cancer Agency VIC Cancer Info Ctr | Available |